Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Retained Earnings (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Retained Earnings for 16 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 99.94% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, up 99.94% year-over-year, with the annual reading at -$1.1 million for FY2025, 99.94% up from the prior year.
  • Retained Earnings hit -$1.1 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$1.7 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $294000.0 in Q1 2025 to a low of -$1.7 billion in Q2 2023.
  • Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.0 billion in 2021.
  • Biggest five-year swings in Retained Earnings: tumbled 161.7% in 2024 and later surged 100.02% in 2025.
  • Year by year, Retained Earnings stood at -$937.6 million in 2021, then grew by 25.73% to -$696.4 million in 2022, then crashed by 143.92% to -$1.7 billion in 2023, then rose by 0.05% to -$1.7 billion in 2024, then skyrocketed by 99.94% to -$1.1 million in 2025.
  • Business Quant data shows Retained Earnings for IRWD at -$1.1 million in Q4 2025, -$1.7 billion in Q3 2025, and -$2.0 million in Q2 2025.